Technical Analysis for CHRS - Coherus BioSciences, Inc.

Grade Last Price % Change Price Change
grade C 18.17 1.51% 0.27
CHRS closed up 1.51 percent on Wednesday, August 5, 2020, on 69 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. It was able to bounce off of its 200 day moving average, an important long-term support line. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline.
Earnings due: Aug 6
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Flat
Historical CHRS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
200 DMA Support Bullish 0.00%
Crossed Above 50 DMA Bullish 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
NR7 Range Contraction 0.00%
NR7-2 Range Contraction 0.00%
Inside Day Range Contraction 0.00%
Fell Below 20 DMA Bearish 1.51%
Fell Below 50 DMA Bearish 1.51%
180 Bearish Setup Bearish Swing Setup 1.51%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Coherus Biosciences, Inc., a late-stage clinical biologics platform company, focuses on developing and commercializing biosimilar products worldwide. Its clinical stage pipeline consists of CHS-0214, an etanercept biosimilar candidate, which is in two Phase III clinical trials for the treatment of rheumatoid arthritis and psoriasis; CHS-1420, an adalimumab biosimilar candidate that has completed a Phase I study to treat psoriasis or rheumatoid arthritis; and CHS-1701, a pegfilgrastim biosimilar candidate, which has completed a Phase I study for the treatment of breast cancer patients exhibiting chemotherapy-induced neutropenia. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus Biosciences, Inc. in April 2012. Coherus Biosciences, Inc. was founded in 2010 and is headquartered in Redwood City, California.
Medicine Biotechnology Biopharmaceutical Immunology Chemotherapy Breast Cancer Rheumatoid Arthritis Psoriasis Immunosuppressants Biosimilar Treatment Of Breast Cancer Recombinant Proteins Etanercept

Is CHRS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.91
52 Week Low 10.8616
Average Volume 1,525,872
200-Day Moving Average 17.87
50-Day Moving Average 18.00
20-Day Moving Average 18.20
10-Day Moving Average 18.20
Average True Range 0.78
ADX 8.57
+DI 18.05
-DI 19.73
Chandelier Exit (Long, 3 ATRs ) 17.08
Chandelier Exit (Short, 3 ATRs ) 19.38
Upper Bollinger Band 18.97
Lower Bollinger Band 17.44
Percent B (%b) 0.48
BandWidth 8.42
MACD Line 0.07
MACD Signal Line 0.14
MACD Histogram -0.0671
Fundamentals Value
Market Cap 932.96 Million
Num Shares 51.3 Million
EPS -2.60
Price-to-Earnings (P/E) Ratio -6.99
Price-to-Sales 3.37
Price-to-Book 17.33
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 18.98
Resistance 3 (R3) 18.94 18.63 18.85
Resistance 2 (R2) 18.63 18.42 18.65 18.80
Resistance 1 (R1) 18.40 18.30 18.52 18.44 18.75
Pivot Point 18.09 18.09 18.15 18.11 18.09
Support 1 (S1) 17.86 17.88 17.98 17.90 17.59
Support 2 (S2) 17.55 17.76 17.57 17.54
Support 3 (S3) 17.32 17.55 17.50
Support 4 (S4) 17.36